<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Cagrilintide</title>
          <meta name="description" content="Curated source summaries for Cagrilintide." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Cagrilintide</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Cagrilintide" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Cagrilintide</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 Research</li><li>2 References</li><li># Cagrilintide</li><li>فارسی</li><li>Українська</li><li>中文</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikidata item</li><li>None</li><li>20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2R)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid</li><li>1415456-99-3</li><li>167312356</li><li>DB18887</li><li>129424923</li><li>AO43BIF1U8</li><li>Interactive image</li><li>CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O</li><li>InChI=1S/C194H312N54O59S2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209)/t100-,101-,102-,103-,104+,105+,106+,107+,108+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-,154-,155-,156-/m0/s1</li><li>Key:LDERDVMBIYGIOI-DDPFBLHVSA-N</li><li>Cagrilintide is a long-acting analogue of amylin . It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide . [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] [ 6 ]</li><li># Research</li><li>A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits. [ 7 ]</li><li># References</li><li>^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} Larsen, Anna T.; Sonne, Nina; Mohamed, Khaled Elhady; Bredtoft, Emma-Marie; Andersen, Frederik; Karsdal, Morten A.; et al. (1 June 2022). "823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats" . Diabetes . 71 (Supplement_1). doi : 10.2337/db22-823-P . S2CID 249259033 .</li><li>^ Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; et al. (December 2021). "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial" . The Lancet . 398 (10317): 2160– 2172. doi : 10.1016/S0140-6736(21)01751-7 . PMID 34798060 . S2CID 244169045 .</li><li>^ Kruse, Thomas; Hansen, Jakob Lerche; Dahl, Kirsten; Schäffer, Lauge; Sensfuss, Ulrich; Poulsen, Christian; et al. (12 August 2021). "Development of Cagrilintide, a Long-Acting Amylin Analogue" . Journal of Medicinal Chemistry . 64 (15): 11183– 11194. doi : 10.1021/acs.jmedchem.1c00565 . ISSN 0022-2623 . PMID 34288673 . S2CID 236175929 .</li><li>^ Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; et al. (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial". The Lancet . 402 (10403): 720– 730. doi : 10.1016/S0140-6736(23)01163-7 . PMID 37364590 . S2CID 259237278 .</li><li>^ D'Ascanio, Antonella M.; Mullally, Jamie A.; Frishman, William H. (8 March 2023). "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity". Cardiology in Review . 32 (Publish Ahead of Print): 83– 90. doi : 10.1097/CRD.0000000000000513 . PMID 36883831 . S2CID 257404657 .</li><li>^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; et al. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models" . Biomedicine & Pharmacotherapy . 156 113842. doi : 10.1016/j.biopha.2022.113842 . ISSN 0753-3322 . PMID 36242844 . S2CID 252881350 .</li><li>^ Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, et al. (2024). "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis" . Indian Journal of Endocrinology and Metabolism . 28 (5): 436– 444. doi : 10.4103/ijem.ijem_45_24 . PMC 11642503 . PMID 39676787 .</li><li>Medicine</li><li>This drug article relating to the gastrointestinal system is a stub . You can help Wikipedia by adding missing information .</li><li>v</li><li>t</li><li>e</li><li>Drugs not assigned an ATC code</li><li>Amylin receptor agonists</li><li>Experimental diabetes drugs</li><li>Cyclic peptides</li><li>Peptide therapeutics</li><li>Gastrointestinal system drug stubs</li><li>Articles with short description</li><li>Short description matches Wikidata</li><li>Use dmy dates from December 2024</li><li>Short description is different from Wikidata</li><li>Articles without EBI source</li><li>Articles without KEGG source</li><li>Drugs with no legal status</li><li>Articles containing unverified chemical infoboxes</li><li>All stub articles</li><li>This page was last edited on 2 January 2026, at 13:08 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://clinicaltrials.gov/search?cond=&term=Cagrilintide" rel="noopener noreferrer" target="_blank">https://clinicaltrials.gov/search?cond=&term=Cagrilintide</a></p>
  <ul>
    <li>Study record managers: refer to the Data Element Definitions if submitting registration or results information.</li><li>Search for terms</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
